ETF Series Solutions Trust Range Cancer Therapeutics ETF
CNCR
CNCR was delisted on the 27th of May, 2025.
10 hedge funds and large institutions have $2.89M invested in ETF Series Solutions Trust Range Cancer Therapeutics ETF in 2016 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 3 increasing their positions, 2 reducing their positions, and 1 closing their positions.
50% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 2
17% more capital inflows, than outflows
Capital inflows: $457K | Capital outflows: $390K
9% less funds holding
Funds holding: 11 → 10 (-1)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$386K |
| 2 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$68.8K |
| 3 |
Ladenburg Thalmann Financial Services
Miami,
Florida
|
+$1.48K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
-$380K |
| 2 |
LPL Financial
San Diego,
California
|
-$8.9K |
| 3 |
Tower Research Capital (TRC)
New York
|
-$1K |
CNCR Hedge Fund Activity: Q3 2016 in Review
10 of the 3,759 institutional investors tracked by Wall St. Rank reported a position in ETF Series Solutions Trust Range Cancer Therapeutics ETF (CNCR) for Q3 2016, worth a combined $2.89M — up 15% from $2.52M a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of CNCR and 0 opened new positions — a net loss of 1 holder — while 2 trimmed existing stakes and 3 added.
The largest buyer was Susquehanna International Group, adding an estimated $386K. The largest seller was Jane Street, cutting an estimated $380K.
- 10 institutional investors held ETF Series Solutions Trust Range Cancer Therapeutics ETF (CNCR) as of Q3 2016, down from 11 in Q2 2016.
- Funds reported $2.89M of ETF Series Solutions Trust Range Cancer Therapeutics ETF stock for Q3 2016, up 15% quarter-over-quarter.
- 0 funds opened new ETF Series Solutions Trust Range Cancer Therapeutics ETF positions in Q3 2016 and 1 closed out, a net change of -1 holder.
- The largest ETF Series Solutions Trust Range Cancer Therapeutics ETF buyer in Q3 2016 was Susquehanna International Group, an estimated $386K added.
- The largest ETF Series Solutions Trust Range Cancer Therapeutics ETF seller in Q3 2016 was Jane Street, an estimated $380K sold.
Based on aggregated 13F filings for Q3 2016.